Caris Life Sciences to Present In-Depth Research with Leading Cancer Centers Reflecting Its Commitment to Improving Patient Outcomes at ASCO 2022

0

Research findings from 45 studies involving more than 20 different types of solid tumors demonstrate the impact of Caris’ approach to molecular profiling across the continuum of cancer care

IRVING, TX, May 26, 2022 /PRNewswire/ — Caris life sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare today, announced that the company and its partners within its Precision Oncology Alliance™ (POA) will collectively present 45 studies on more than 20 different types of solid tumors at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting of June 3-7, 2022 (Booth #22081).

“The breadth of research presented at ASCO illustrates the power of comprehensive molecular profiling and large-scale collaboration across more than 60 sites to address some of today’s greatest challenges in cancer care and oncology. precision,” said Chadi Nabhan, MD, MBA, FACP, President of the Caris Precision Oncology Alliance. “The results of these studies could help improve outcomes for patients with difficult-to-treat cancers and initiate new approaches to care for diverse tumor types and patient populations.”

“At Caris, our goal is to enable clinicians to make the best treatment choices, researchers to discover new targets, and the biopharmaceutical industry to develop the next breakthrough drugs,” said David Spetzler, MS, Ph.D., MBA, President and Scientific Director of Caris. “These presentations show how our scientists and POA partners are using Caris’ unique AI-based platform – which combines DNA (Whole Exome), RNA (Whole Transcriptome), and protein profiling data. with real-life clinical evidence from over 378,000 lifelong cases – to unravel the complexities of cancer.Ultimately, these discoveries could advance personalized cancer care and improve outcomes for many patients.

The Caris Precision Oncology Alliance includes 65 cancer centers and academic institutions across United States and beyond. These institutions have early access to Caris’ extensive database and artificial intelligence platform to establish evidence-based standards for cancer profiling and molecular testing in oncology. By leveraging the comprehensive genomic, transcriptomic and proteomic data available through Caris Molecular Profiling, Caris seeks to provide this network with the ability to prioritize treatment options and determine clinical trial opportunities that may benefit their patients. POA members can also become part of a growing portfolio of biopharma-sponsored biomarker-directed trials. Additionally, as a member of the POA, institutions have access to Caris CODEai™, the industry’s most comprehensive data solution with cancer treatment information and evidence of actual clinical outcomes for over 275,000 patients spanning over one million data points per patient.

Three oral discussions focus on difficult-to-treat tumors and aggressive tumor types with low survival rates:

  • Comprehensive genomic and transcriptomic characterization of small bowel adenocarcinoma (poster number: 6)
    June 4, 2022, 1:15 p.m. to 2:45 p.m. CDT
  • Biological and prognostic relevance of epigenetic regulatory genes in high-grade gliomas (HGG) (Poster Number: 3570)
    June 5, 2022, 11:30 a.m.-1:00 p.m. CDT
  • Surfaceome Profiling Reveals Unique Therapeutic Vulnerabilities in Small Cell Lung Cancer (SCLC) Transcriptional Subtypes (Poster Number: 142)
    June 6, 2022, 11:30 a.m.-1:00 p.m. CDT

Other notable studies among the 45 accepted abstracts address key topics in oncology such as the tumor microenvironment, mechanisms of therapeutic resistance and rare biomarkers:

  • The tumor microenvironment and immune infiltration landscape of KRAS mutant pancreatic ductal adenocarcinomas (PDAC) versus colorectal adenocarcinomas (CRC) (Poster Number: 127)
    June 4, 2022, 8:00-11:00 a.m. CDT
  • Claudin 18 (CLDN18) gene expression and associated molecular profile in gastric cancer (GC) (Poster Number: 36)
    June 4, 2022, 8:00-11:00 a.m. CDT
  • The Differential Response to Immune Checkpoint Inhibitors in Colorectal and Endometrial Cancer Patients According to Different Mismatch Repair Impairments (Poster Number: 418)
    June 4, 2022, 8:00-11:00 a.m. CDT
  • Characterization of TIM3 and its ligands in colorectal cancer (Poster Number: 341)
    June 4, 2022, 8:00-11:00 a.m. CDT
  • Exploring the nuances between BRCA1 and 2: a multiomics analysis (Poster number: 456)
    June 4, 2022, 1:15-4:15 p.m. CDT
  • S1314 Correlative analysis of ATM, RB1, ERCC2 and FANCC mutations and pathological complete response (pT0) to cystectomy after neoadjuvant chemotherapy (NAC) in patients with muscle invasive bladder cancer (MIBC): implications for the bladder preservation (Poster Number: 72)
    June 4, 2022, 1:15-4:15 p.m. CDT
  • Reversion Mutations in the BRCA1 or BRCA2 Genes: Mechanism(s) of Resistance in Patients Treated with Platinum-Based Agents or Poly(ADP-ribose) Polymerase (PARP) Inhibitors (Poster Number: 124)
    June 5, 2022, 8:00-11:00 a.m. CDT
  • Characterization of MET Exon 14 (METex14) Skipping Alterations in Non-Small Cell Lung Cancer (NSCLC) Using Whole Transcriptome Sequencing (WTS) (Poster ID: 108)
    June 6, 2022, 8:00-11:00 a.m. CDT

Poster and abstract abstracts highlighting this research will be available onsite at Caris booth 22081. Full abstracts will be available via the official website ASCO website on May 26.

About Caris Life Sciences

Caris life sciences® (Caris) is the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare and improve patient outcomes. Through comprehensive molecular profiling (whole exome and whole transcriptome sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris created the Clinico-Genomics Database scale and cognitive computing needed to analyze and unravel the molecular complexity of disease. This information provides an unparalleled resource and the ideal pathway for conducting fundamental basic research to accelerate discovery for detection, diagnosis, monitoring, therapy selection and drug development to improve the human condition.

With a primary focus on cancer, Caris’ suite of state-of-the-art molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular pattern that helps patients, doctors and researchers better detect, diagnose and treat patients. Caris’ latest advancement, which is currently available within its Precision Oncology Alliance, is a blood-based circulating nucleic acid sequencing (cNAS) assay that combines comprehensive molecular analysis (whole exome and transcriptome sequencing whole from blood) and serial monitoring – making it the most powerful liquid biopsy test ever developed.

Based at Irving, TXCaris has offices in Phoenix, New York, denver, Tokyo, Japan and Basel, Switzerland. Caris provides services across the United States, Europe, Asia and other international markets. To learn more, please visit CarisLifeSciences.com or follow us on Twitter (@CarisLS).

Caris Life Sciences media contact:
Lisa Burger
[email protected]
469.822.9330

SOURCES Caris Life Sciences

Share.

Comments are closed.